N 6022 is primarily used as a selective antagonist for the P2X7 receptor, making it a valuable tool in research focused on inflammation and immune responses. It is applied in studies related to neuroinflammation, chronic pain, and autoimmune diseases due to its ability to modulate ATP-mediated signaling in immune cells. Its high selectivity allows researchers to investigate the role of the P2X7 receptor without significant off-target effects. N 6022 has also been explored in preclinical models of neurodegenerative conditions such as Alzheimer's disease, where P2X7 activation contributes to pathological inflammation. Additionally, it supports the development of therapeutic strategies targeting purinergic signaling pathways in inflammatory disorders.